Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin + genistein versus ivacaftor in cystic fibrosis with class III mutation
2014-000817-30Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- May 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of curcumin, genistein and ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Difference in lung function (%FEV1), Airway resistance (Rint and bodybox) and 1 more. Started May 2014; status: completed.
02
Drugs
curcumingenisteinivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2014-000817-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000817-30.